<template>
  <!-- BANNER OF THE ALX PAGE -->

  <div class="alx_banner">
    <div class="alx_banner_content container">
      <h2 class="alx_banner_content_title">ALX009</h2>
      <br />

      <p class="alx_banner_content_description">
        ALX-009 is a first-in class orphan drug candidate for Cystic Fibrosis
        (CF) patients. <br /><br />
        It consists in the combination of two endogenous substances,
        hypothiocyanite (OSCN-) and lactoferrin, exhibiting antimicrobial
        properties compensating the defective innate immune system in CF
        patients. ALX-009 is presented as a solution for inhalation for the
        symptomatic treatment of lung infections.
      </p>
    </div>
    <div class="btn container">
      <p>
        <a href="#overview"><i class="fas fa-binoculars"></i> Overview</a>
      </p>
      <p>
        <a href="#efficacy"><i class="fas fa-bolt"></i> Efficacy</a>
      </p>
      <p>
        <a href="#further_reading"
          ><i class="fas fa-book-open"></i> Further reading</a
        >
      </p>
    </div>
  </div>
  <br />
  <br />
  <!-- OVERVIEW PART -->

  <div id="overview" class="container alx_overview">
    <h2 class="alx_part_title">OVERVIEW</h2>
    <br />
    <h3>ALX-009 scientific and medical rationale.</h3>
    <p>
      <br />
      The genetic causes of CF are linked to the mutation of a single gene, the
      cftr (cystic fibrosis transmembrane conductance regulator) gene. This gene
      codes for the CFTR membrane proteins involved in the ion exchange between
      the cell and the lumen. In the lung, ionic equilibrium is important to
      preserve the protective action of the Airway Surface Liquid (ASL) and
      mucus. However, in CF patients, ASL, mucus volumes and compositions are
      modified. The ASL normally contains bactericidal/bacteriostatic products
      in solution that are less or not present in the ASL of CF patients. In
      addition, the volume of the ASL of CF patients is reduced with increased
      salt content; both factors dehydrate the mucus that becomes thick and
      accumulates at the surface of cells.
    </p>
    <br />
    <div>
      <p class="alx_page_schema_desciption">
        Impaired OSCN- and lactoferrin in CF patients lungs’ defense
      </p>
      <img
        class="alx_page_schema"
        src="../assets/alx_page/alx_page_first_schemajpg.jpg"
        alt=""
      />
    </div>
    <br />
    <p>
      OSCN- and lactoferrin are among the bactericidal compounds that are
      deficient in the ASL of CF patients. OSCN- is a potent large spectrum
      antimicrobial compound whereas lactoferrin is a multifunctional protein
      that inactivates/kills bacteria. Presence of OSCN- is significantly
      influenced by the CFTR function. Indeed, the precursor molecule SCN-
      transits by the CFTR channel to the ASL where it reacts with H2O2 via a
      lactoperoxidase enzymatic reaction to produce OSCN-. However, in CF
      patients, the SCN- traffic via the CFTR channel is inefficient and the
      secretion of lactoperoxidase seems also impaired by the obstruction of
      goblet cells by the thick mucus covering the CF lung epithelia. OSCN-
      production is then compromised. Lactoferrin secretion is also blocked by
      the mucus, reducing even more the natural ASL defense capacity. OSCN- is a
      highly reactive compound that oxidizes free thiol radicals of proteins to
      created disulfide bonds that perturb the bacterial physiology. Lactoferrin
      may act by direct interaction with bacterial cell membranes by depriving
      bacteria of iron due to its iron chelator activity. By providing both
      molecules, ALX-009, a fixed combination of OSCN- and lactoferrin, will
      contribute to restore the natural capacity of the lung to fight against
      infections.
    </p>
    <br />
    <h3>Mode of Action :</h3>
    <br />
    <div>
      <a target="_blank" href="https://vimeo.com/243802312"
        ><img
          class="alx_page_second_schema"
          src="../assets/alx_page/alx_page_second_schemajpg.jpg"
          alt=""
      /></a>
    </div>
  </div>
  <br />
  <br />

  <!-- EFFICACY PART -->

  <div id="efficacy" class="container efficacy">
    <h2 class="alx_part_title">EFFICACY</h2>
    <br />
    <section>
      <h3>
        ALX-009 (OSCN-/bLF) – a therapeutic option to fight broader bacterial
        infections
      </h3>
      <br />
      <div>
        <p class="alx_page_schema_description">
          Tests performed by Alaxia or in collaboration with Queen’s University
          Belfast or Colorado State University
        </p>
        <img
          class="alx_page_schema"
          src="../assets/alx_page/alx_page__efficacy_first_schemajpg.png"
          alt=""
        />
      </div>
    </section>

    <br />
    <br />

    <section>
      <h3>
        Time killing profile of ALX-009 against emergent Cystic Fibrosis
        pathogens or Selected agent
      </h3>
      <br />
      <p class="alx_page_schema_description">
        Achromobacter spp, Pseudomonas aeruginosa, Burkholderia cepacia complex,
        Stenotrophomonas maltophilia, Burkholderia pseudomallei
      </p>
      <div class="img_efficacy">
        <img
          class="alx_page_schema_small"
          src="../assets/alx_page/alx_page__efficacy_second_schemajpg.jpg"
          alt=""
        />
        <img
          class="alx_page_schema_small"
          src="../assets/alx_page/alx_page__efficacy_third_schemajpg.jpg"
          alt=""
        />
      </div>
    </section>
    <br />
    <br />
    <section>
      <h3>ALX-009 (OSCN-/bLF) – bactericidal effect in biological matrices</h3>
      <br />
      <p class="alx_page_schema_description">
        In contrast with antibiotics, ALX-009 activity is not altered by complex
        structures such as biofilm and/or sputum that are present in lung
        infections
      </p>
      <div class="img_efficacy">
        <img
          class="alx_page_schema_small"
          src="../assets/alx_page/alx_page__efficacy_fourth_schemajpg.jpg"
          alt=""
        />
        <img
          class="alx_page_schema_small"
          src="../assets/alx_page/alx_page__efficacy_six_schemajpg.jpg"
          alt=""
        />
      </div>
      <p>
        ALX-009 kills bacteria embedded in P. aeruginosa biofilms at
        concentrations similar to planktonic cultures. Presence of bLF allows
        decreasing OSCN- dose
      </p>
    </section>
  </div>
  <br />
  <br />

  <!-- FURTHER READING PART -->
  <div id="further_reading" class="container further_reading">
    <h2 class="alx_part_title">FURTHER READING</h2>
    <br />
    <article>
      <h3>
        The lactoperoxidase system functions in bacterial clearance of airways.
      </h3>
      <p>
        Gerson C, Sabater J, Scuri M, Torbati A, Coffey R, Abraham JW, Lauredo
        I, Forteza R, Wanner A, Salathe M, Abraham WM, Conner GE. Am J Respir
        Cell Mol Biol. 2000 Jun;22(6):665-71.
      </p>
    </article>

    <br />

    <article>
      <h3>
        A component of innate immunity prevents bacterial biofilm development.
      </h3>
      <p>
        Singh PK, Parsek MR, Greenberg EP, Welsh MJ. Nature. 2002 May 30;
        417(6888):552-5.
      </p>
    </article>

    <br />

    <article>
      <h3>
        Dual oxidases represent novel hydrogen peroxide sources supporting
        mucosal surface host defenses.
      </h3>
      <p>
        Geiszt M, Witta J, Baffi J, Lekstrom K, Leto TL. The FASEB J. 2003;
        17(11):1502-4.
      </p>
    </article>

    <br />

    <article>
      <h3>Lactoperoxidase and human airway host defense.</h3>
      <p>
        Wijkstrom-Frei C, El-Chemaly S, Ali-Rachedi R, Gerson C, Cobas MA,
        Forteza R, Salathe M, Conner GE. Cell Mol. Biol. 2003 Aug; 29(2):206-12.
      </p>
    </article>

    <br />

    <article>
      <h3>
        Loss of microbicidal activity and increased formation of biofilm due to
        decreased lactoferrin activity in patients with cystic fibrosis.
      </h3>
      <p>
        Rogan MP, Taggart CC, Greene CM, Murphy PG, O’Neill SJ, McElvaney NG. J
        Infect Dis. 2004 Oct 1;190(7):1245-53. Epub 2004 Aug 26.
      </p>
    </article>

    <br />

    <article>
      <h3>
        Antimicrobial proteins and polypeptides in pulmonary innate defence.
      </h3>
      <p>
        Rogan MP, Geraghty P, Greene CM, O’Neill SJ, Taggart CC, McElvaney NG.
        Respir. Res. 2006; 7:29.
      </p>
    </article>

    <br />

    <article>
      <h3>
        A novel host defense system of airways is defective in cystic fibrosis.
      </h3>
      <p>
        Moskwa P, Lorentzen D, Excoffon KJ, Zabner J, McCray PB Jr, Nauseef W M,
        Dupuy C, Bánfi B. Am. J. Respir. Crit. Care Med. 2007 Jan 15;
        175(2):174-83.
      </p>
    </article>

    <br />

    <article>
      <h3>
        A new model of cystic fibrosis pathology: lack of transport of
        glutathione and its thiocyanate conjugates
      </h3>
      <p>
        .Childers M, Eckel G, Himmel A, Caldwell J. Med Hypotheses.
        2007;68(1):101-12.
      </p>
    </article>

    <br />

    <article>
      <h3>
        The lactoperoxidase system links anion transport to host defense in
        cystic fibrosis.
      </h3>
      <p>
        Conner GE, Wijkstrom-Frei C, Randell SH, Fernandez VE, Salathe M. FEBS
        Lett. 2007 Jan 23; 581(2):271-8.
      </p>
    </article>

    <br />

    <article>
      <h3>
        The pseudomonas toxin pyocyanin inhibits the dual oxidase based
        antimicrobial system as it imposes oxidative stress on airway epithelial
        cells.
      </h3>
      <p>
        Rada B, Lekstrom K, Damian S, Dupuy C, Leto TL. J Immunol. 2008 Oct 1;
        181(7):4883-93.
      </p>
    </article>

    <br />

    <article>
      <h3>Mechanisms and function of DUOX in epithelia of the lung.</h3>
      <p>Fischer H. Antioxid. 2009 Oct; 11(10):2453-65.</p>
    </article>

    <br />

    <article>
      <h3>
        Thiocyanate: a potentially useful therapeutic agent with host defense
        and antioxidant properties.
      </h3>
      <p>Chandler JD, Day BJ. Biochem Pharmacol. 2012 Dec 1;84(11):1381-7.</p>
    </article>

    <br />

    <article>
      <h3>
        Selective metabolism of hypothiocyanous acid by mammalian thioredoxin
        reductase promotes lung innate immunity and antioxidant defense.
      </h3>
      <p>
        Chandler JD, Nichols DP, Nick JA, Hondal RJ, Day BJ. J Biol Chem. 2013
        Jun 21;288(25):18421-8.
      </p>
    </article>

    <br />

    <article>
      <h3>
        In vitro antiviral activity of hypothiocyanite against A/H1N1/2009
        pandemic influenza virus.
      </h3>
      <p>
        Cegolon L, Salata C, Piccoli E, Juarez V, Palu G, Mastrangelo G,
        Calistri A. Int J Hyg Environ Health. 2014 Jan;217(1):17-22.
      </p>
    </article>

    <br />

    <article>
      <h3>
        Combination of hypothiocyanite and lactoferrin (ALX-109) enhances the
        ability of tobramycin and aztreonam to eliminate Pseudomonas aeruginosa
        biofilms growing on cystic fibrosis airway epithelial cells.
      </h3>
      <p>
        Moreau-Marquis S, Coutermarsh B, Stanton BA. J Antimicrob Chemother.
        2015 Jan;70(1):160-6.
      </p>
    </article>

    <br />

    <article>
      <h3>
        Activity of hypothiocyanite and lactoferrin (ALX-009) against
        respiratory cystic fibrosis pathogens in sputum.
      </h3>
      <p>
        Tunney MM, Payne JE, McGrath SJ, Einarsson GG, Ingram RJ, Gilpin DF,
        Juarez-Perez V, Elborn JS J Antimicrob Chemother. 2018 Sep 14.
      </p>
    </article>

    <br />
  </div>
  <br />
  <br />
</template>

<script>
export default {};
</script>

<style lang="scss" scoped>
// GENERAL STYLE OF PAGE
.container {
  text-align: justify;
}
.alx_part_title {
  font-size: 24px;
}
.alx_page_schema {
  width: 40vw;
}
.alx_page_schema_small {
  width: 30vw;
}
.alx_page_schema_description {
  font-style: italic;
}

// ALX BANNER
.alx_banner {
  position: relative;
  height: 250px;
  margin-top: -40px;
  background-color: #025293;
  padding-top: 36px;
  padding-bottom: 36px;
  h2,
  p {
    color: white;
  }
}
.alx_banner_content_title {
  font-size: 36px;
}
.alx_banner_content_description {
  text-align: justify;
  font-size: 14px;
}
.btn {
  position: absolute;
  bottom: 10px;
  display: flex;
  justify-content: center;
  align-items: center;
  width: 100%;
  margin: 0 auto;
  margin-bottom: 8px;
}
a {
  text-decoration: none;
  cursor: pointer;
  opacity: 0.8;
  background: white;
  color: #025293;
  margin-right: 12px;
  border: 1px solid white;
  border-radius: 4px;
  padding: 8px;
  transition: 0.3s all ease-in-out;
  &:hover {
    opacity: 0.6;
  }
}

// ALX OVERVIEW PART
.alx_page_second_schema {
  width: 60vw;
  margin: 0 auto;
}
.img_efficacy {
  display: flex;
  justify-content: space-around;
}

// ALX FURTHER READING PART
article p {
  font-style: italic;
}
article h3 {
  font-size: 14px;
}
</style>
